DDInter1233 DDInter1747
Mitotane is an adrenolytic isomer of the insecticide dichlorodiphenyldichloroethane (DDD) - itself a metabolite of dichlorodiphenyltrichloroethane (DDT) - that inhibits cells of the adrenal cortex and their production of hormones. It has been in use since 1959 for the treatment of inoperable adrenocortical carcinoma and is used off-label for the management of Cushing's syndrome.
Tasimelteon is a selective dual melatonin receptor agonist indicated for the treatment of Non-24-Hour Sleep-Wake Disorder (N24HSWD). Occurring commonly in blind individuals without light perception, this condition is often characterized by periods of night-time insomnia and day-time sleepiness. In blind individuals, a lack of light stimulation causes an extension of the 24-hour circadian cycle and can lead to progressively delayed sleep onset. By activating melatonin receptors MT1 and MT2 in the suprachiasmatic nucleus of the brain, tasimelteon has been shown to improve sleep by resynchronizing the circadian rhythm through its "non-photic" mechanism. Tasimelteon is currently the only drug available for the treatment of N24HSWD and was granted orphan drug status by the FDA in 2010.
Mitotane {u} (Compound) resembles {v} (Compound) Carbinoxamine
Mitotane {u} (Compound) binds {v} (Gene) CYP11B1
Mitotane {u} (Compound) upregulates {v} (Gene) ADGRE5
Mitotane {u} (Compound) is included by {v} (Pharmacologic Class) Cytochrome P450 3A4 Inducers
Mitotane {u} (Compound) downregulates {v} (Gene) PEG10
Mitotane {u} (Compound) causes {v} (Side Effect) Digestion impaired
Mitotane (Compound) resembles Carbinoxamine (Compound)
Mitotane (Compound) binds CYP11B1 (Gene)
Mitotane (Compound) upregulates ADGRE5 (Gene)
Mitotane (Compound) is included by Cytochrome P450 3A4 Inducers (Pharmacologic Class)
Mitotane (Compound) downregulates PEG10 (Gene)
Mitotane (Compound) causes Digestion impaired (Side Effect)